新昌創展(01781.HK)清盤呈請押後
新昌創展控股(01781.HK)公布,正全力推進重組方案的製定和實施過程,有關與One Oak的融資協議,公司、共同臨時清盤人與One Oak協定將初始融資最後截止日期延後至明年3月11日,及將進一步融資最後截止日期延後至2022年4月15日。
此外,有關公司的有關若干訴訟及清盤呈請,香港司法機構將有關2020年第HCCW 403號的清盤呈請押後至2022年1月3日,呈請人可以在前述日期前隨時申請進行聆訊。
公司股份自2020年7月2日起暫停買賣,並將續停牌至另行通知為止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.